Alan Edmund Walts - 19 Sep 2025 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc. (ELOX)

Reporting relationship: Director
Issuer ticker: ELOX
Reported as of: 19 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 May 2026, 16:44:52 UTC
Prior SEC filing: 28 Jan 2025
Next SEC filing: 10 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Sumit Aggarwal, Attorney-in-Fact

Key filing fact

Alan Edmund Walts filed Form 4 for Eloxx Pharmaceuticals, Inc. (ELOX) on 08 May 2026.

Key facts

This page summarizes Alan Edmund Walts's Form 4 filing for Eloxx Pharmaceuticals, Inc. (ELOX).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 08 May 2026, 16:44.

Change

Previous filing in this sequence was filed on 28 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001853544 Primary reporting owner

Walts Alan Edmund

Relationship: Director
Address: C/O ELOXX PHARMACEUTICALS, INC., P.O. BOX 274, ARLINGTON
Signature: /s/ Sumit Aggarwal, Attorney-in-Fact
Signature date: 08 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELOX transaction

Common Stock

Options Exercise

Transaction value
Shares: +1,875
Change %: +14%
Price
Shares after: 15,567
Date: 24 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELOX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +395,680
Change %
Price: $0.000000^*
Shares after: 395,680
Date: 19 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 395,680
Exercise price: $0.1500
Footnotes: F2

ELOX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -1,875
Change %: -50%
Price: $0.000000^*
Shares after: 1,875
Date: 24 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,875
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

The stock option vested as to 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

Footnote F3

The RSUs vested as to 50% on the first anniversary of January 24, 2024, and the remaining amount vested in two equal annual installments thereafter.